Literature DB >> 6419958

Treatment of the restless legs syndrome with carbamazepine: a double blind study.

W Telstad, O Sørensen, S Larsen, P E Lillevold, P Stensrud, R Nyberg-Hansen.   

Abstract

One hundred and seventy four patients suffering from the restless legs syndrome were examined in a double blind, between patient, placebo controlled study in general practice for five weeks to investigate the effects of carbamazepine and placebo on the syndrome. The syndrome was more common among middle aged women with relatively low systolic blood pressure. The median haemoglobin concentration was about average for the population, but the severity of the symptoms seemed to increase with decreasing concentrations of haemoglobin. Both placebo and carbamazepine showed a significant therapeutic effect (p less than 0.01). Carbamazepine was significantly more effective than placebo (p less than or equal to 0.03). The significant therapeutic effect of placebo in restless legs showed that only double blind controlled trials can confirm the efficacy of suggested treatments.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419958      PMCID: PMC1444746          DOI: 10.1136/bmj.288.6415.444

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Treatment of the restless legs syndrome with clonazepam.

Authors:  W B Matthews
Journal:  Br Med J       Date:  1979-03-17

2.  Clonazepam: effective treatment for restless legs syndrome in uraemia.

Authors:  D J Read; T G Feest; M A Nassim
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-03

3.  The cardiovascular disease study in Norwegian counties. Results from first screening.

Authors:  K Bjartveit; O P Foss; T Gjervig
Journal:  Acta Med Scand Suppl       Date:  1983

4.  Effect of diclofenac and naproxen on gastroduodenal mucosa.

Authors:  M Osnes; S Larsen; W Eidsaunet; E Thom
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 5.  Antiepileptic drugs: pharmacokinetic and clinical aspects.

Authors:  S I Johannessen
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

  5 in total
  29 in total

1.  Restless Legs Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

Review 2.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Restless legs syndrome and pregnancy: prevalence, possible pathophysiological mechanisms and treatment.

Authors:  R Gupta; M Dhyani; T Kendzerska; S R Pandi-Perumal; A S BaHammam; P Srivanitchapoom; S Pandey; M Hallett
Journal:  Acta Neurol Scand       Date:  2015-10-19       Impact factor: 3.209

Review 4.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Efficacy and safety of pramipexole in restless legs syndrome.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

6.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

7.  Restless legs syndrome.

Authors:  C Bernick; L Z Stern
Journal:  West J Med       Date:  1986-08

Review 8.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

Review 9.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

Review 10.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.